Ligand Pharmaceuticals (LGND) Profit After Tax (2010 - 2026)
Ligand Pharmaceuticals recorded quarterly Profit After Tax of -$13.3 million in Q1 2026, down 129.8% quarter-over-quarter from $44.8 million in Q4 2025, and up 68.56% year-over-year from -$7.9 million in Q1 2025.
Ligand Pharmaceuticals' Profit After Tax history runs 17 years deep, the most recent figure standing at -$13.3 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 68.56% year-over-year to -$13.3 million; the TTM figure through Mar 2026 stood at $153.6 million (up 215.79% YoY), while the FY2025 annual figure was $124.5 million, up 3186.63% from the prior year.
- Profit After Tax came in at -$13.3 million for Q1 2026 at Ligand Pharmaceuticals, down from $44.8 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $117.3 million in Q3 2025 to a low of -$51.9 million in Q2 2024.
- A 5-year average of $7.5 million and a median of -$895000.0 in 2022 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax slumped 2642.82% in 2023 and surged 1735.15% in 2025, its largest moves.
- Ligand Pharmaceuticals' Profit After Tax stood at -$17.5 million in 2022, then jumped by 213.54% to $19.9 million in 2023, then slumped by 256.59% to -$31.1 million in 2024, then jumped by 244.06% to $44.8 million in 2025, then slumped by 129.8% to -$13.3 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$13.3 million, $44.8 million, and $117.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Ligand Pharmaceuticals | 4.61 Bn | 3.83 Bn | 48.45 Mn | -13.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.35 Mn |
| Dec 31, 2025 | 44.78 Mn |
| Sep 30, 2025 | 117.27 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | -42.45 Mn |
| Dec 31, 2024 | -31.09 Mn |
| Sep 30, 2024 | -7.17 Mn |
| Jun 30, 2024 | -51.91 Mn |
| Mar 31, 2024 | 86.14 Mn |
| Dec 31, 2023 | 19.85 Mn |
| Sep 30, 2023 | -10.27 Mn |
| Jun 30, 2023 | 2.29 Mn |
| Mar 31, 2023 | 41.95 Mn |
| Dec 31, 2022 | -17.49 Mn |
| Sep 30, 2022 | 404,000.00 |
| Jun 30, 2022 | -895,000.00 |
| Mar 31, 2022 | -15.39 Mn |
| Dec 31, 2021 | -5.42 Mn |
| Sep 30, 2021 | 20.34 Mn |
| Jun 30, 2021 | 30.73 Mn |
| Mar 31, 2021 | 18.11 Mn |
| Dec 31, 2020 | 5.76 Mn |
| Sep 30, 2020 | -6.70 Mn |
| Jun 30, 2020 | 22.09 Mn |
| Mar 31, 2020 | -24.13 Mn |
| Dec 31, 2019 | -7.37 Mn |
| Sep 30, 2019 | -15.25 Mn |
| Jun 30, 2019 | -14.42 Mn |
| Mar 31, 2019 | 666.34 Mn |
| Dec 31, 2018 | -42.48 Mn |
| Sep 30, 2018 | 67.36 Mn |
| Jun 30, 2018 | 73.16 Mn |
| Mar 31, 2018 | 45.28 Mn |
| Dec 31, 2017 | -42.48 Mn |
| Sep 30, 2017 | 67.36 Mn |
| Jun 30, 2017 | 73.16 Mn |
| Mar 31, 2017 | 45.28 Mn |
| Dec 31, 2016 | -3.13 Mn |
| Sep 30, 2016 | 1.05 Mn |
| Jun 30, 2016 | -6.17 Mn |
| Mar 31, 2016 | 6.61 Mn |
| Dec 31, 2015 | 6.34 Mn |
| Sep 30, 2015 | 199.17 Mn |
| Jun 30, 2015 | 22.03 Mn |
| Mar 31, 2015 | 754,000.00 |
| Dec 31, 2014 | 7.06 Mn |
| Sep 30, 2014 | 1.28 Mn |
| Jun 30, 2014 | 1.59 Mn |
| Mar 31, 2014 | 2.10 Mn |
| Dec 31, 2013 | 1.87 Mn |
| Sep 30, 2013 | 1.97 Mn |
| Jun 30, 2013 | 6.09 Mn |
| Mar 31, 2013 | 1.30 Mn |
| Dec 31, 2012 | 2.59 Mn |
| Sep 30, 2012 | -194,000.00 |
| Jun 30, 2012 | -4.33 Mn |
| Mar 31, 2012 | 1.13 Mn |
| Dec 31, 2011 | 4.69 Mn |
| Sep 30, 2011 | -4.18 Mn |
| Jun 30, 2011 | -422,000.00 |
| Mar 31, 2011 | 9.63 Mn |
| Dec 31, 2010 | 4.76 Mn |
| Sep 30, 2010 | -11.84 Mn |
| Jun 30, 2010 | -290,000.00 |